INFRASTRUCTURE NATIONALE EN PHENOGENOMIQUE SOURIS

Rodent models (used at 75% in Europe) are essential for basic and preclinical research, to understand the genome, to generate human disease models and to test therapeutics in vivo. Integrative approaches are required to understand biological and pathophysiological processes in the organisms, with exchanges and communication between cells, organs and the environment. PHENOMIN was granted in 2011 by the Investissements d’Avenir to build a research infrastructure for Mouse Phenogenomics with 3 specialized nodes: TAAM, ICS and CIPHE. In 2016, it integrated the infrastructure CELPHEDIA listed on the French roadmap in 2021. PHENOMIN has now been renewed for the period of 2020-2024 with 4 main objectives: 1) serve the whole scientific community and provide access to state-of-the-art genetic engineering, zootechnics, phenotyping, archiving and distribution of rodent models via robust and cross-validated techniques considering the 3R rules, ethics and animal welfare; 2) increase the knowledge of mammalian genome; 3) understand the role of genetic variations at the origin of diseases, in particular, rare diseases; 4) open new opportunities for innovation and development of therapies and drugs. PHENOMIN has developed a scientific R&D program and has implemented a strong coordinated infrastructure certified ISO9001/2015 with a unique website portal for users. It is a major player in the international strategic phenogenomic effort, through INFRAFRONTIER, the ESFRI-identified pan-European infrastructure for Mouse functional genomics and IMPC (International Mouse Phenotyping Consortium), to build the 1^st comprehensive, functional catalogue of a mammalian genome. PHENOMIN has applied mouse genetics to analyse disease mechanisms and has facilitated access to models created in the frame of IMPC and the Foundation for Rare Diseases, to benefit advanced fundamental research and human health, part of the strategic plan from the National Alliance for life sciences and health (AVIESAN).